Receipt of a significant purchase order
The Management Board of Selvita S.A. with its registered office in Krakow (“Issuer”) hereby informs that on June 28, 2021, the Issuer’s affiliated company – Selvita Inc. (“Company”) received an order from a biotechnology company based in the United States (the “Client”) with a total value of $ 1,020,000 (PLN 3,853,356 converted at the rate of USD 1 = PLN 3,7778) (“Purchase Order”) under the framework agreement concluded between the above-mentioned parties on March 17, 2020 (the “Agreement”). The services will be executed throughout a next year, starting from July 1, 2021 to June 30, 2022. The subject of the Purchase Order is provision of chemical synthesis services in the area of drug discovery activities, including synthesis, purification and characterization of organic intermediates and final compounds that will be used by the Client in in vitro and in vivo assays.
The other terms of the Purchase Order do not differ from those commonly used for this type of contracts.
The Issuer’s Management Board considers the conclusion of the Purchase Order as significant due to its value.
Legal basis: Art. 17 par. 1 of MAR
Representatives of the Company:
- Bogusław Sieczkowski – President of the Management Board
- Miłosz Gruca – Vice President of the Management Board